BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

265 related articles for article (PubMed ID: 37845136)

  • 1. EMAS position statement: Testosterone replacement therapy in older men.
    Kanakis GA; Pofi R; Goulis DG; Isidori AM; Armeni E; Erel CT; Fistonić I; Hillard T; Hirschberg AL; Meczekalski B; Mendoza N; Mueck AO; Simoncini T; Stute P; van Dijken D; Rees M; Lambrinoudaki I
    Maturitas; 2023 Dec; 178():107854. PubMed ID: 37845136
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prostate-specific antigen changes and prostate cancer in hypogonadal men treated with testosterone replacement therapy.
    Coward RM; Simhan J; Carson CC
    BJU Int; 2009 May; 103(9):1179-83. PubMed ID: 19154450
    [TBL] [Abstract][Full Text] [Related]  

  • 3. EMAS position statement: Testosterone replacement therapy in the aging male‏.
    Dimopoulou C; Ceausu I; Depypere H; Lambrinoudaki I; Mueck A; Pérez-López FR; Rees M; van der Schouw YT; Senturk LM; Simonsini T; Stevenson JC; Stute P; Goulis DG
    Maturitas; 2016 Feb; 84():94-9. PubMed ID: 26614257
    [TBL] [Abstract][Full Text] [Related]  

  • 4. European Academy of Andrology (EAA) guidelines on investigation, treatment and monitoring of functional hypogonadism in males: Endorsing organization: European Society of Endocrinology.
    Corona G; Goulis DG; Huhtaniemi I; Zitzmann M; Toppari J; Forti G; Vanderschueren D; Wu FC
    Andrology; 2020 Sep; 8(5):970-987. PubMed ID: 32026626
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Injection of testosterone may be safer and more effective than transdermal administration for combating loss of muscle and bone in older men.
    Borst SE; Yarrow JF
    Am J Physiol Endocrinol Metab; 2015 Jun; 308(12):E1035-42. PubMed ID: 25898953
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of Testosterone Replacement Therapy on Sexual Function and Hypogonadal Symptoms in Men with Hypogonadism.
    Pencina KM; Travison TG; Cunningham GR; Lincoff AM; Nissen SE; Khera M; Miller MG; Flevaris P; Li X; Wannemuehler K; Bhasin S
    J Clin Endocrinol Metab; 2024 Jan; 109(2):569-580. PubMed ID: 37589949
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adding liraglutide to lifestyle changes, metformin and testosterone therapy boosts erectile function in diabetic obese men with overt hypogonadism.
    Giagulli VA; Carbone MD; Ramunni MI; Licchelli B; De Pergola G; Sabbà C; Guastamacchia E; Triggiani V
    Andrology; 2015 Nov; 3(6):1094-103. PubMed ID: 26447645
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Testosterone replacement therapy in hypogonadal men at high risk for prostate cancer: results of 1 year of treatment in men with prostatic intraepithelial neoplasia.
    Rhoden EL; Morgentaler A
    J Urol; 2003 Dec; 170(6 Pt 1):2348-51. PubMed ID: 14634413
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Quality of Life and Sexual Function Benefits of Long-Term Testosterone Treatment: Longitudinal Results From the Registry of Hypogonadism in Men (RHYME).
    Rosen RC; Wu F; Behre HM; Porst H; Meuleman EJH; Maggi M; Romero-Otero J; Martinez-Salamanca JI; Jones TH; Debruyne FMJ; Kurth KH; Hackett GI; Quinton R; Stroberg P; Reisman Y; Pescatori ES; Morales A; Bassas L; Cruz N; Cunningham GR; Wheaton OA;
    J Sex Med; 2017 Sep; 14(9):1104-1115. PubMed ID: 28781213
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of testosterone replacement therapy withdrawal and re-treatment in hypogonadal elderly men upon obesity, voiding function and prostate safety parameters.
    Yassin A; Nettleship JE; Talib RA; Almehmadi Y; Doros G
    Aging Male; 2016; 19(1):64-9. PubMed ID: 26742589
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hypogonadism in the man with erectile dysfunction: what to look for and when to treat.
    Lazarou S; Morgentaler A
    Curr Urol Rep; 2005 Nov; 6(6):476-81. PubMed ID: 16238923
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Testosterone treatment is not associated with increased risk of prostate cancer or worsening of lower urinary tract symptoms: prostate health outcomes in the Registry of Hypogonadism in Men.
    Debruyne FM; Behre HM; Roehrborn CG; Maggi M; Wu FC; Schröder FH; Jones TH; Porst H; Hackett G; Wheaton OA; Martin-Morales A; Meuleman E; Cunningham GR; Divan HA; Rosen RC;
    BJU Int; 2017 Feb; 119(2):216-224. PubMed ID: 27409523
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Testosterone replacement therapy among elderly males: the Testim Registry in the US (TRiUS).
    Bhattacharya RK; Khera M; Blick G; Kushner H; Miner MM
    Clin Interv Aging; 2012; 7():321-30. PubMed ID: 22956867
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Role of Testosterone in the Elderly: What Do We Know?
    Barone B; Napolitano L; Abate M; Cirillo L; Reccia P; Passaro F; Turco C; Morra S; Mastrangelo F; Scarpato A; Amicuzi U; Morgera V; Romano L; Calace FP; Pandolfo SD; De Luca L; Aveta A; Sicignano E; Trivellato M; Spena G; D'Alterio C; Fusco GM; Vitale R; Arcaniolo D; Crocetto F
    Int J Mol Sci; 2022 Mar; 23(7):. PubMed ID: 35408895
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prostate Safety Events During Testosterone Replacement Therapy in Men With Hypogonadism: A Randomized Clinical Trial.
    Bhasin S; Travison TG; Pencina KM; O'Leary M; Cunningham GR; Lincoff AM; Nissen SE; Lucia MS; Preston MA; Khera M; Khan N; Snabes MC; Li X; Tangen CM; Buhr KA; Thompson IM
    JAMA Netw Open; 2023 Dec; 6(12):e2348692. PubMed ID: 38150256
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Testosterone Therapy: What We Have Learned From Trials.
    Corona G; Torres LO; Maggi M
    J Sex Med; 2020 Mar; 17(3):447-460. PubMed ID: 31928918
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Influence of demographic factors and biochemical characteristics on the prostate-specific antigen (PSA) response to testosterone replacement therapy.
    Rhoden EL; Morgentaler A
    Int J Impot Res; 2006; 18(2):201-5. PubMed ID: 16177827
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recurrence of prostate cancer in patients receiving testosterone supplementation for hypogonadism.
    Gray H; Seltzer J; Talbert RL
    Am J Health Syst Pharm; 2015 Apr; 72(7):536-41. PubMed ID: 25788507
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Testosterone replacement therapy does not promote priapism in hypogonadal men with sickle cell disease: 12-month safety report.
    Morrison BF; Reid M; Madden W; Burnett AL
    Andrology; 2013 Jul; 1(4):576-82. PubMed ID: 23606509
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Testosterone replacement therapy and prostate cancer. The current position 67 years after the Huggins myth].
    Rinnab L; Gust K; Hautmann RE; Küfer R
    Urologe A; 2009 May; 48(5):516-22. PubMed ID: 19296069
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.